Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huairu Granules + CAPOX + PD-1 inhibitors for conversion therapy in HER2-negative unresectable gastric cancer
ChiCTR2600123039Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Apr 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of huaier granule in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sichuan Cancer Hospital. Primary endpoint: R0 resection rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
huaier granule
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600123039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123039.